# OpenOnco: Bridging the Gap Between Diagnostic Innovation and Care Delivery

## Grant Proposal for Pharma & Foundation Partners
*January 2026*

---

## The Opportunity

Cancer diagnostic testing has transformed from episodic events into a continuous conversation with diseaseâ€”spanning inherited risk, early detection, treatment selection, response monitoring, and survivorship surveillance. The liquid biopsy industry has achieved remarkable innovation, bringing transformative tests to patients faster than ever before.

**Yet a fundamental gap persists**: Healthcare delivery infrastructure has not kept pace with diagnostic innovation.

Test developers excel at creating sophisticated assays. But they are laboratories, not care delivery organizations. Meanwhile, the clinical systems that should provide integrationâ€”oncology practices, health systems, guidelines bodiesâ€”move slowly and struggle to keep pace.

**The result**: Patients receive cutting-edge test results without support infrastructure to act on them. Community oncologists face tests not yet in guidelines without decision support. Care transitions become failure points where context is lost.

**OpenOnco exists to bridge this gap**â€”vendor-neutral, patient-centered, helping patients and oncologists understand which tests exist, what results mean, and what comes next.

---

## What We've Built (With Zero Funding)

### The Most Comprehensive Liquid Biopsy Database in the World

| Category | Tests Catalogued | Description |
|----------|------------------|-------------|
| **MRD** (Molecular Residual Disease) | 41 | Post-treatment surveillance for recurrence |
| **ECD** (Early Cancer Detection) | 27 | Screening including MCED tests |
| **HCT** (Hereditary Cancer Testing) | 33 | Inherited risk assessment |
| **TDS** (Treatment Decision Support) | 41 | Comprehensive genomic profiling |
| **Total** | **142 tests** | Across the full testing continuum |

### Vendor Coverage

**68 diagnostic companies** catalogued, from industry leaders to emerging innovators:
- Major labs: Foundation Medicine, Guardant Health, Tempus, Natera, Exact Sciences
- Specialty players: Adaptive Biotechnologies, GRAIL, Caris Life Sciences
- Emerging innovators: DELFI Diagnostics, Freenome, Personalis
- International players: Burning Rock, Geneseeq, IMBdx

### Regulatory Intelligence

For each test, we track:
- FDA approval/clearance status (PMA, 510(k), De Novo, Breakthrough Device)
- CLIA/CAP laboratory certifications
- CE-IVDR status for international context
- Medicare coverage policies (NCD/LCD linkage)

### Coverage Reality Check (In Development)

Our signature feature: Cross-referencing vendor marketing claims against actual payer policies
- Medicare LCD policy integration
- Private payer medical policy tracking
- Prior authorization guidance
- Appeal letter templates

---

## Traction: Proof of Demand (December 2025 â€“ January 2026)

### User Growth

| Metric | Value | Context |
|--------|-------|---------|
| **Unique Visitors** | 1,307 | Last 30 days |
| **Page Views** | 3,418 | Strong engagement |
| **Test Detail Views** | 3,250 | Deep product usage |
| **Week-over-Week Growth** | 240% | 73 â†’ 248 users |

### Engagement Quality

| Metric | Value | What It Means |
|--------|-------|---------------|
| **Tests Viewed per User** | 7.8 | Users actively researching, not bouncing |
| **Visitor â†’ Test Conversion** | 47% | Nearly half engage with product |
| **Time to First Test View** | 52 sec | Users find value immediately |
| **Bounce Rate** | 58% | Healthy for informational resource |

### Audience Quality: Reaching the Right People

| Traffic Source | Share | Signal |
|----------------|-------|--------|
| **LinkedIn** | 52% | Professional/clinical audience |
| **Google Search** | 36% | Organic discovery, SEO working |
| **Microsoft Teams** | 7% | Enterprise sharing in health systems |

**LinkedIn as #1 referrer proves we're reaching oncologists, lab directors, and healthcare professionalsâ€”not general consumers.**

Microsoft Teams traffic indicates the platform is being shared internally within health systemsâ€”early signal of enterprise adoption potential.

### Geographic Reach

| Country | Share |
|---------|-------|
| ðŸ‡ºðŸ‡¸ United States | 67% |
| ðŸ‡¬ðŸ‡§ United Kingdom | 7% |
| ðŸ‡©ðŸ‡ª Germany | 3% |
| ðŸ‡¨ðŸ‡¦ Canada | 2% |
| ðŸ‡¦ðŸ‡º Australia | 2% |

**33% international traffic with zero localization investment** = global demand for this resource.

### Content Interest: Market Validation

| Category | Interest Share | Market Signal |
|----------|---------------|---------------|
| **MRD** | 39% | Fastest-growing oncology dx segment |
| **ECD** | 28% | MCED driving patient awareness |
| **CGP/TDS** | 19% | Mature but active market |
| **HCT** | 13% | Established category |

**MRD dominating user interest aligns with the $5B+ market opportunity in recurrence monitoring.**

---

## What We've Accomplished: Summary

### Built (With $0)
- âœ… Comprehensive database of 142 liquid biopsy tests
- âœ… Coverage of 68 diagnostic vendors
- âœ… Regulatory status tracking (FDA, CLIA, CE-IVDR)
- âœ… Medicare coverage policy integration
- âœ… Modern web platform (React, serverless architecture)
- âœ… Analytics infrastructure (PostHog, Vercel)
- âœ… Automated monitoring (5 crawlers for regulatory/coverage changes)

### Achieved (In <60 Days)
- âœ… 1,300+ healthcare professionals reached
- âœ… 3,200+ test detail views
- âœ… 240% week-over-week growth
- âœ… LinkedIn as primary referrer (professional audience)
- âœ… Enterprise sharing behavior (MS Teams traffic)
- âœ… Global reach (33% international)

### All Without
- âŒ Paid marketing
- âŒ Sales team
- âŒ External funding
- âŒ Full-time staff

---

## The Vision: Testing as the Unifying Thread

One thing connects every stage of the cancer journey: **molecular testing**. Tests are ordered at every phase. Results are objective and portable. Data should carry context across care transitions.

Testing can become the unifying thread through fragmented cancer careâ€”**if an integration layer exists to make it so.**

### The Testing Continuum

1. **Hereditary Cancer Testing** â†’ "Am I at risk?"
2. **Early Cancer Detection** â†’ "Do I have cancer?"
3. **Treatment Decision Support** â†’ "What treatment will work?"
4. **Response Monitoring** â†’ "Is treatment working?"
5. **Recurrence Monitoring** â†’ "Is it coming back?"

Each stage hands off to the next. Throughout this continuum, OpenOnco provides the integration layerâ€”helping patients and oncologists understand which tests exist, what's covered, what results mean, and what comes next.

---

## Why Pharma Should Care

### For Diagnostic Developers

**Problem**: You've built an excellent test. Patients don't understand it. Oncologists don't know when to order it. Coverage is inconsistent.

**OpenOnco's Value**:
- Vendor-neutral platform increases category awareness
- Accurate coverage information reduces ordering friction
- Patient education reduces support burden
- Category-level advocacy benefits all players

### For Pharmaceutical Companies

**Problem**: Your therapies depend on companion diagnostics. Patients eligible for your drugs aren't getting tested. Coverage gaps delay treatment initiation.

**OpenOnco's Value**:
- Increase appropriate testing for your biomarker
- Educate patients about testing options that lead to your therapy
- Navigate coverage to accelerate treatment access
- Track real-world testing patterns and coverage outcomes

### For All Stakeholders

**The structural gap between diagnostic innovation and care delivery hurts everyone.**

Patients don't get tested appropriately. Tests don't reach patients who need them. Therapies don't reach patients who would benefit. Coverage remains a barrier rather than an enabler.

**OpenOnco is the integration layer the ecosystem needs.**

---

## Funding Request

### Phase 1: Foundation Building (Months 1-6) â€” $150,000

**Database Expansion**
- Complete coverage policy integration (Medicare + top 10 private payers)
- Clinical evidence summaries for each test
- Performance data standardization

**Patient Tools**
- "Questions for your oncologist" generator
- Coverage eligibility checker
- Testing journey roadmap by cancer type

**Technical Infrastructure**
- Patient portal foundation
- Data collection framework (crowdsourced TAT, costs)

### Phase 2: Patient Engagement (Months 7-12) â€” $200,000

**Patient Portal Launch**
- Profile creation (cancer type, stage, insurance)
- Personalized test recommendations
- Surveillance reminders
- Community features (curated patient experiences)

**Coverage Reality Check**
- Full payer policy cross-reference
- Prior authorization guidance
- Appeal letter templates
- Financial assistance finder

**Crowdsourced Intelligence**
- Real turnaround time data
- Actual out-of-pocket costs
- Coverage outcome tracking

### Phase 3: Clinical Integration (Months 13-18) â€” $150,000

**Provider Tools**
- Decision support for community oncologists
- Pre-guideline evidence summaries
- Patient handouts and resources

**Outcome Tracking**
- Coverage success rates
- Testing completion rates
- Time from result to action

**Total Ask: $500,000 over 18 months**

---

## What Partners Get

### Visibility
- Logo on sponsor page
- Attribution in relevant content
- Quarterly impact reports

### Intelligence
- Aggregated, anonymized data on testing patterns
- Coverage outcome trends
- Patient navigation insights
- Category-level market intelligence

### Mission Alignment
- Support vendor-neutral patient education
- Advance appropriate testing adoption
- Reduce coverage barriers
- Enable the ecosystem you depend on

### What We Won't Do
- Favor sponsors in test presentation
- Compromise editorial independence
- Share individual patient data
- Recommend specific tests over others

**Our credibility depends on vendor neutrality. Your investment supports the platform, not preferential treatment.**

---

## Team

### Alex Dickinson, Founder

Founded OpenOnco after losing his sister Ingrid to cancer. Experienced the firsthand frustration of navigating fragmented testing information, inconsistent coverage, and lack of patient-centered resources.

Background in [relevant experience]. Mission-driven to ensure other patients and families have better support navigating the testing landscape.

### Advisory Network
- Oncology clinical advisors
- Diagnostic industry veterans
- Patient advocacy leaders
- Healthcare policy experts

---

## The Ask

We're seeking **$500,000 in grant funding over 18 months** from pharma partners and foundations aligned with our mission.

**What we've proven**:
- Demand exists (1,300+ users, 240% growth, zero marketing)
- Audience is right (LinkedIn #1, enterprise sharing)
- Content resonates (7.8 tests/user, 47% conversion)
- Market timing is right (MRD interest leading)

**What we need**:
- Runway to build patient portal
- Resources to expand coverage intelligence
- Capacity to develop provider tools

**What you get**:
- Ecosystem infrastructure that benefits everyone
- Market intelligence on testing patterns
- Mission-aligned investment in patient education
- A healthier diagnostic testing ecosystem

---

## Contact

**OpenOnco**
www.openonco.org

Alex Dickinson
Founder
[email]

---

*OpenOnco is a 501(c)(3) non-profit organization. All contributions are tax-deductible to the extent allowed by law.*

---

**Document Version**: 1.0
**Date**: January 2026
**Confidential**: For potential grant partners only
